179 related articles for article (PubMed ID: 9210893)
21. Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer.
Chelis L; Xenidis N; Amarantidis K; Prassopoulos P; Chamalidou E; Neanidis K; Mikroulis D; Chatzaki E; Karakitsos P; Kakolyris S
Chemotherapy; 2010; 56(5):353-8. PubMed ID: 20926858
[TBL] [Abstract][Full Text] [Related]
22. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Ferrigno D; Buccheri G
Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
[TBL] [Abstract][Full Text] [Related]
23. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Bunn PA; Kelly K
Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
[TBL] [Abstract][Full Text] [Related]
24. Comment: vinorelbine and gemcitabine--new antineoplastic drugs.
Guchelaar HJ
Ann Pharmacother; 1996 Nov; 30(11):1343. PubMed ID: 8913428
[No Abstract] [Full Text] [Related]
25. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.
Shirai T; Hirose T; Noda M; Ando K; Ishida H; Hosaka T; Ozawa T; Okuda K; Ohnishi T; Ohmori T; Horichi N; Adachi M
Lung Cancer; 2006 May; 52(2):181-7. PubMed ID: 16563558
[TBL] [Abstract][Full Text] [Related]
28. [Second line chemotherapy for pancreatic cancer].
Park JY
Korean J Gastroenterol; 2011 Apr; 57(4):207-12. PubMed ID: 21519173
[TBL] [Abstract][Full Text] [Related]
29. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Mavroudis D
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
[No Abstract] [Full Text] [Related]
30. New anticancer drugs in Europe.
Armand JP
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():70-93. PubMed ID: 9210890
[No Abstract] [Full Text] [Related]
31. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
[TBL] [Abstract][Full Text] [Related]
32. [The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?].
Grossi F; de Marinis F; Frontini L; Gridelli C
Tumori; 2008; 94(3):5-14. PubMed ID: 18705422
[No Abstract] [Full Text] [Related]
33. New agents in the management of advanced non-small cell lung cancer.
Carney DN
Semin Oncol; 1998 Aug; 25(4 Suppl 9):83-8. PubMed ID: 9728591
[TBL] [Abstract][Full Text] [Related]
34. Role of induction chemotherapy in resectable N2 non-small cell lung cancer.
de Marinis F; Tedesco B; Treggiari S; De Santis S; Cipri A; Belli R; Condò S; Ariganello O; Di Molfetta M; Migliorino MR
J Thorac Oncol; 2007 May; 2(5 Suppl):S31-4. PubMed ID: 17457228
[No Abstract] [Full Text] [Related]
35. Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer.
Johnson D; Tonato M
Semin Oncol; 1999 Feb; 26(1 Suppl 4):1-2. PubMed ID: 10201514
[No Abstract] [Full Text] [Related]
36. A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Kotsakis A; Hatzidaki D; Vamvakas L; Vardakis N; Kalykaki A; Bozionelou V; Androulakis N; Kalbakis K; Saridaki Z; Georgoulias V; Agelaki S
Anticancer Res; 2010 Oct; 30(10):4335-42. PubMed ID: 21036760
[TBL] [Abstract][Full Text] [Related]
37. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
Büyükçelik A; Yalçin B; Utkan G; Doruk H
Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
[No Abstract] [Full Text] [Related]
38. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
[TBL] [Abstract][Full Text] [Related]
39. [Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].
Zhao M; Yang H; He J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):550-3. PubMed ID: 21645463
[No Abstract] [Full Text] [Related]
40. Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Clarke SJ; Boyer MJ
Med J Aust; 1997 Jun; 166(S1):S14-6. PubMed ID: 9201199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
